Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Olema Pharmaceuticals, Inc. has received a consensus rating of "Moderate Buy" from six ratings firms, with five analysts recommending a buy and one a sell.
• The average 12-month price target for Olema Pharmaceuticals among analysts is $24.00, with HC Wainwright setting a target of $30.00.
• As of now, shares of Olema Pharmaceuticals are trading at $5.26, having a market capitalization of approximately $360.99 million.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $24.00.

Several analysts recently commented on the company. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a report on Monday, April 28th. Citigroup raised their target price on Olema Pharmaceuticals from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Tuesday. The Goldman Sachs Group dropped their target price on Olema Pharmaceuticals from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Zacks Research raised Olema Pharmaceuticals to a "strong sell" rating in a report on Monday. Finally, JPMorgan Chase & Co. raised their target price on Olema Pharmaceuticals from $28.00 to $29.00 and gave the stock an "overweight" rating in a report on Thursday.

Olema Pharmaceuticals Trading Down 0.2%

Shares of NASDAQ:OLMA opened at $5.26 on Friday. The business's 50-day moving average is $4.62 and its 200 day moving average is $4.64. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.09 and a quick ratio of 15.22. The firm has a market capitalization of $360.99 million, a P/E ratio of -2.66 and a beta of 1.92. Olema Pharmaceuticals has a 1 year low of $2.86 and a 1 year high of $13.93.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.08). On average, research analysts predict that Olema Pharmaceuticals will post -2.33 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Olema Pharmaceuticals

A number of hedge funds have recently bought and sold shares of OLMA. Bain Capital Life Sciences Investors LLC purchased a new position in shares of Olema Pharmaceuticals in the fourth quarter valued at approximately $43,551,000. Paradigm Biocapital Advisors LP increased its holdings in shares of Olema Pharmaceuticals by 32.7% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,304,970 shares of the company's stock valued at $42,588,000 after purchasing an additional 1,801,370 shares during the last quarter. MPM Bioimpact LLC increased its holdings in shares of Olema Pharmaceuticals by 0.6% in the first quarter. MPM Bioimpact LLC now owns 2,930,446 shares of the company's stock valued at $11,018,000 after purchasing an additional 17,896 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Olema Pharmaceuticals by 6.0% in the fourth quarter. Vanguard Group Inc. now owns 2,685,009 shares of the company's stock valued at $15,654,000 after purchasing an additional 152,117 shares during the last quarter. Finally, Lightspeed Management Company L.L.C. acquired a new stake in shares of Olema Pharmaceuticals in the fourth quarter valued at approximately $11,257,000. Hedge funds and other institutional investors own 91.78% of the company's stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.